ARTICLES BY ESTEL GRACE MASANGKAY
Eli Lilly, Adocia To Co-Develop Ultra-Rapid Insulin12/23/2014
Eli Lilly announced that it has entered into a global licensing partnership with clinical-stage biotech firm Adocia to co-develop an ultra-rapid insulin based on the latter’s proprietary technology as treatment for Type 1 and Type 2 diabetes.
Halozyme, Janssen Link To Develop Subcutaneous Drugs12/22/2014
Halozyme Therapeutics announced that it has signed up with Janssen Biotech in a global collaboration to develop and market Janssen's subcutaneous treatments using the former's ENHANZE technology.
GSK Joins Consortium To Further Ebola Vaccine Development12/18/2014
GlaxoSmithKline announced that it has joined an EU consortium with three other research institutions in order to further advance the development of GSK’s vaccine against the deadly virus Ebola.
TWi Biotech Gets U.S. And Taiwan Approval For AC-201 Phase 2 Trial12/17/2014
TWi Pharmaceuticals announced that its subsidiary TWi Biotechnology has scored regulatory approvals from both U.S. and Taiwan authorities for the protocol of a Phase 2 clinical trial investigating its lead drug AC-201.
Abbott Wraps Up Acquisition Of Russian Firm Veropharm12/17/2014
Abbott announced that it has completed its acquisition of leading Russian pharma manufacturer Veropharm.
GSK Files MAA For Volibris To Treat PAH In EU12/16/2014
GlaxoSmithKline reported that it has filed a variation of Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for its drug Volibris (ambrisentan) to include pulmonary arterial hypertension (PAH) in its indication as a combination treatment.
Boston’s IND For Type 2 Diabetes Drug Accepted By FDA12/16/2014
Boston Therapeutics announced that its Investigational New Drug Application (IND) for BTI-320 as treatment for Type 2 diabetes and to help manage weight has been accepted for review by the U.S. Food and Drug Administration (FDA).
La Jolla Licenses LJPC-501 To Washington University12/15/2014
La Jolla Pharmaceuticals announced that it has entered into an exclusive global license agreement with the George Washington University concerning intellectual property rights of its drug LJPC-501 as a treatment for hypotension and shock.
Pfizer Signs Immunotherapy Deal With iTeos Therapeutics12/12/2014
Belgian biotech firm iTeos Therapeutics announced that it has signed a strategic collaboration with Pfizer for the licensing of several pre-clinical compounds against cancer immunosuppression targets.
AstraZeneca’s Moventig For OIC Approved In The EU12/12/2014
AstraZeneca announced that the European Commission has green-lighted its drug Moventig (naloxegol) as treatment for opioid-induced constipation (OIC) in adult patients who haven’t been successfully treated with laxatives in the EU.